LifeSci Capital Remains a Buy on Prime Medicine, Inc. (PRME)
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Cory Jubinville maintained a Buy rating on Prime Medicine (PRME) with a $6.00 price target. Meanwhile, TipRanks launched the RANK ETF tracking its US Momentum Analysts Index. Other analysts' views include H.C. Wainwright issuing a Buy and Morgan Stanley maintaining a Hold on PRME.
LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Prime Medicine, Inc. today and set a price target of $6.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Jubinville, PhD is ranked #511 out of 12332 analysts.
In addition to LifeSci Capital, Prime Medicine, Inc. also received a Buy from H.C. Wainwright’s Arthur He CFA in a report issued on July 9. However, on July 8, Morgan Stanley maintained a Hold rating on Prime Medicine, Inc. (NASDAQ: PRME).